Merck’s Vioxx Extension Study Does Not Show An Increased Risk Of Heart Attack
This article was originally published in The Pink Sheet Daily
Preliminary analysis shows that there was not a statistically significant difference in the risk of confirmed thrombotic cardiovascular events for patients previously on Vioxx compared to placebo.
You may also be interested in...
The company corrected the description of statistical methods used in the Vioxx study.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue